Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer

被引：23

作者：

Ferro, Matteo ^{[1
]}

Di Mauro, Marina ^{[2
]}

Cimino, Sebastiano ^{[2
]}

Morgia, Giuseppe ^{[2
,3
]}

Lucarelli, Giuseppe ^{[4
]}

Abu Farhan, Abdal Rahman ^{[5
]}

Vartolomei, Mihai Dorin ^{[5
]}

Porreca, Angelo ^{[6
]}

Cantiello, Francesco ^{[4
]}

Damiano, Rocco ^{[4
]}

Busetto, Gian Maria ^{[7
]}

Del Giudice, Francesco ^{[7
]}

Hurle, Rodolfo ^{[8
]}

Perdona, Sisto ^{[9
]}

Borghesi, Marco ^{[10
]}

Bove, Pierluigi ^{[11
]}

Autorino, Riccardo ^{[12
]}

Crisan, Nicolae ^{[13
]}

Marchioni, Michele ^{[14
]}

Schips, Luigi ^{[14
]}

Soria, Francesco ^{[15
]}

Mari, Andrea ^{[16
]}

Minervini, Andrea ^{[16
]}

Veccia, Alessandro ^{[11
,17
]}

Battaglia, Michele ^{[18
]}

Terracciano, Daniela ^{[19
]}

Musi, Gennaro ^{[1
]}

Cordima, Giovanni ^{[1
]}

Muto, Matteo ^{[20
]}

Mirone, Vincenzo ^{[21
]}

de Cobelli, Ottavio ^{[1
]}

Russo, Giorgio Ivan ^{[2
]}

机构：

[1] European Inst Oncol, Div Urol, Milan, Italy

[2] Univ Catania, Urol Sect, Dept Surg, Catania, Italy

[3] Ist Oncol Mediterraneo IOM, Urol Sect, Viagrande, Italy

[4] Magna Graecia Univ Catanzaro, Dept Urol, Catanzaro, Italy

[5] Univ Med & Pharm, Dept Cell & Mol Biol, Targu Mures, Romania

[6] Abano Terme Hosp, Dept Urol, Padua, Italy

[7] Sapienza Univ Rome, Dept Urol, Rome, Italy

[8] Ist Ricovero & Cura Carattere Sci, Ist Clin Humanitas, Clin & Res Hosp, Dept Urol, Milan, Italy

[9] Fdn G Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Urogynecol Dept, Naples, Italy

[10] Univ Bologna, Dept Urol, Bologna, Italy

[11] Tor Vergata Univ Rome, Urol Unit, Dept Expt Med & Surg, Div Urol, Rome, Italy

[12] Virginia Commonwealth Univ, Div Urol, Richmond, VA USA

[13] Univ Med & Pharm Cluj Napoca, Dept Urol, Cluj Napoca, Romania

[14] SS Annunziata Hosp, Urol Unit, Dept Med Oral & Biotechnol Sci, Chieti, Italy

[15] Univ Studies Torino, Dept Surg Sci, Div Urol, Turin, Italy

[16] Univ Florence, Careggi Hosp, Unit Oncol Minimally Invas Urol & Androl, Dept Urol, Florence, Italy

[17] Univ Brescia, ASST Osped Civili, Dept Med & Surg Specialties, Urol Unit,Radiol Sci & Publ Hlth, Brescia, Italy

[18] Univ Bari, Urol Androl & Kidney Transplantat Unit, Dept Emergency & Organ Transplantat, Bari, Italy

[19] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy

[20] SG Moscati Hosp, Radiotherapy Unit, Avellino, Italy

[21] Univ Naples Federico II, Urol Unit, Dept Neurosci Sci Reprod & Odontostomatol, Naples, Italy

来源：

TRANSLATIONAL ANDROLOGY AND UROLOGY | 2021年 / 10卷 / 02期

关键词：

Bladder cancer (BC); inflammation; prognosis; outcomes; immune system; PROGNOSTIC NUTRITIONAL INDEX; PROGRESSION; RECURRENCE; MARKERS; SAFE;

D O I：

10.21037/tau-20-1272

中图分类号：

R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

摘要：

Background: An accurate and early diagnosis of bladder cancer (BC) is essential to offer patients the most appropriate treatment and the highest cure rate. For this reason, patients need to be best stratified by class and risk factors. We aimed to develop a score able to better predict cancer outcomes, using serum variables of inflammation. Methods: A total of 1,510 high-risk non-muscle invasive bladder cancer (NMIBC) patients were included in this retrospective observational study. Patients with pathologically proven T1 HG/G3 at first TURBT were included. Systemic combined inflammatory score (SCIS) was calculated according to systemic inflammatory markers (SIM), modified Glasgow prognostic score (mGPS), and prognostic nutritional index (PNI) dichotomized (final score from 0 to 3). Results: After 48 months of follow-up (IQR 40.0-73.0), 727 patients recurred (48.1%), 485 progressed (32.1%), 81 died for cancer (7.0%), and 163 died for overall causes (10.8%). Overall, 231 (15.3%) patients had concomitant Cis, 669 (44.3%) patients had multifocal pathology, 967 (64.1%) patients had tumor size>3 cm. Overall, 357 (23.6%) patients received immediate-intravesical therapy, 1,356 (89.8%) received adjuvant intravesical therapy, of which 1,382 (91.5 %) received BCG, 266 (17.6% ) patients received mitomycin C, 4 (0.5%) patients received others intravesical therapy. Higher SCIS was independently predictive of recurrence (hazard ratio HR 1.5, 1.3 and 2.2) and cancer specific mortality for SCIS 0 and 3 (HR: 1.61 and 2.3), and overall mortality for SCIS 0 and 3 (HR: 2.4 and 3.2). Conversely, SCIS was not associated with a higher probability of progression. Conclusions: The inclusion of the SCIS in clinical practice is simple to apply and can help improve the prediction of cancer outcomes. It can identify patients with high-grade BC who are more likely to experience disease mortality.

引用

页码：626 / +

页数：14

共 29 条

[1] cvauroc: Command to compute cross-validated area under the curve for ROC analysis after predictive modeling for binary outcomes [J].